Related Experiment Video
Updated: Jan 18, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Recent and anticipated novel drug approvals (2Q 2025 through 1Q 2026)
Matthew H Rim1, Collin Dean1, Enela Aliaj1
1Northwestern Medicine, Chicago, IL, USA.
Purpose:
Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by providing updates on new and anticipated novel drug approvals.
Summary:
Selected drug approvals anticipated in the 12-month period covering the second quarter of 2025 through the first quarter of 2026 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics, as selected from 58 novel drugs awaiting US Food and Drug Administration (FDA) approval. This year's pipeline features novel therapies for rare diseases, targeted cancer treatments, and new agents for various diseases states.
Conclusion:
Novel therapies continue to strengthen the current drug pipeline.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
09:55Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Regulation
Drug Products: Biologics, Biosimilars and Interchangeables
Clinically Relevant Drug Product Specifications: Methods of Establishment